All In Biotech

Drug Trial Radar · NCT06592924

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 830 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

830

Planned (sponsor's estimate)

Start

May 28, 2025

Primary completion

Mar 14, 2031

Study completion Apr 15, 2031

Sponsor

Lead sponsor
Canadian Cancer Trials GroupResearch network
Sponsor type
Research network
Collaborators
ECOG-ACRIN Cancer Research Group; NRG Oncology; Alliance for Clinical Trials in Oncology; SWOG Cancer Research Network
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).

Conditions

  • Prostate Cancer (Adenocarcinoma)

Interventions

  • AbirateroneDrug

    Assigned prior to enrollment

  • EnzalutamideDrug

    Assigned prior to enrollment

  • ApalutamideDrug

    Assigned prior to enrollment

  • Darolutamide (BAY 1841788)Drug

    Assigned prior to enrollment

  • DocetaxelDrug

    Assigned at enrollment

  • ADTDrug

    Physician's choice. Assigned prior to enrollment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 39 months

Locations

395 sites in 4 countries. Site status is shown where the registry gives one.

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska · Recruiting

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska · Recruiting

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska · Recruiting

  • Alaska Women's Cancer Care

    Anchorage, Alaska · Recruiting

  • Katmai Oncology Group

    Anchorage, Alaska · Recruiting

  • Providence Alaska Medical Center

    Anchorage, Alaska · Recruiting

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska · Recruiting

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona · Recruiting

  • Kaiser Permanente-Anaheim

    Anaheim, California · Recruiting

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California · Recruiting

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California · Recruiting

  • Kaiser Permanente-Bellflower

    Bellflower, California · Recruiting

  • Tower Cancer Research Foundation

    Beverly Hills, California · Recruiting

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California · Recruiting

  • Mercy Cancer Center - Carmichael

    Carmichael, California · Recruiting

  • Mercy San Juan Medical Center

    Carmichael, California · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • Mercy Cancer Center - Elk Grove

    Elk Grove, California · Recruiting

  • Stanford Cancer Center Emeryville

    Emeryville, California · Recruiting

  • Kaiser Permanente-Fontana

    Fontana, California · Recruiting

  • Kaiser Permanente South Bay

    Harbor City, California · Recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Recruiting

  • Kaiser Permanente-Irvine

    Irvine, California · Recruiting

  • City of Hope Antelope Valley

    Lancaster, California · Recruiting

  • City of Hope at Long Beach Elm

    Long Beach, California · Recruiting

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California · Recruiting

  • Los Angeles General Medical Center

    Los Angeles, California · Recruiting

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Kaiser Permanente West Los Angeles

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Mercy Cancer Center

    Merced, California · Recruiting

  • Providence Queen of The Valley

    Napa, California · Recruiting

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California · Recruiting

  • Kaiser Permanente-Ontario

    Ontario, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California · Recruiting

  • VA Palo Alto Health Care System

    Palo Alto, California · Recruiting

  • Kaiser Permanente - Panorama City

    Panorama City, California · Recruiting

  • Keck Medical Center of USC Pasadena

    Pasadena, California · Recruiting

Showing 40 of 395 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.